- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00003141
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors
A Pilot Study of Intensive Chemotherapy With Peripheral Stem Cell Support for Infants With Malignant Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctors to give higher doses of chemotherapy drugs and kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating infants with malignant brain or spinal cord tumors.
Study Overview
Status
Detailed Description
OBJECTIVES:
- Determine the maximum tolerated dose of thiotepa in infants with malignant brain or spinal cord tumors receiving intensive chemotherapy.
- Determine the feasibility and toxicity of intensive chemotherapy with peripheral blood stem cell (PBSC) rescue in these patients.
- Assess the feasibility of harvesting PBSCs in these patients.
- Determine the complete response rate and overall event-free survival rate in patients treated with this regimen.
OUTLINE: This is a pilot, multicenter study.
Patients undergo surgery for diagnosis and maximal tumor resection.
Within 6 weeks of surgery or when stable, patients begin induction chemotherapy comprising cisplatin IV over 6 hours on day 0; vincristine IV on days 0, 7, and 14; cyclophosphamide IV over 1 hour on days 1-2; and etoposide IV over 1 hour on days 0-2. Twenty four hours after the last cyclophosphamide dose, patients receive filgrastim (G-CSF) subcutaneously (SC) and undergo peripheral blood stem cell harvest 2 days later. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
Within 6 weeks after induction chemotherapy, patients receive consolidation chemotherapy comprising carboplatin IV over 2 hours on days 0-1 followed immediately by escalating doses of thiotepa IV over 2 hours. Patients then undergo peripheral blood stem cell transplantation 48 hours after the last thiotepa dose. Patients receive G-CSF SC daily on days 3 to 21. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
Patients experiencing dose-limiting toxicity due to thiotepa are removed from the study.
Patients are followed at 4 weeks, every 3 months for 1 year, every 6 months for 3 years, and then annually for 3 years or until relapse.
PROJECTED ACCRUAL: A total of 83 patients will be accrued for this study within 1 year.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Western Australia
-
Perth, Western Australia, Australia, 6001
- Princess Margaret Hospital for Children
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- Children's & Women's Hospital of British Columbia
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- CancerCare Manitoba
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital For Sick Children
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Allan Blair Cancer Centre at Pasqua Hospital
-
-
-
-
California
-
Duarte, California, United States, 91010-3000
- City of Hope Comprehensive Cancer Center
-
Los Angeles, California, United States, 90095-1781
- Jonsson Comprehensive Cancer Center at UCLA
-
Los Angeles, California, United States, 90027
- Childrens Hospital Los Angeles
-
Los Angeles, California, United States, 90048-1865
- Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
-
Madera, California, United States, 93638-8762
- Children's Hospital Central California
-
Oakland, California, United States, 94609
- Children's Hospital and Research Center Oakland
-
Orange, California, United States, 92868
- Children's Hospital of Orange County
-
Sacramento, California, United States, 95825
- Kaiser Permanente Medical Center - Oakland
-
San Francisco, California, United States, 94115
- UCSF Helen Diller Family Comprehensive Cancer Center
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Children's Hospital Center for Cancer and Blood Disorders
-
Denver, Colorado, United States, 80218
- Presbyterian - St. Luke's Medical Center
-
-
Connecticut
-
Farmington, Connecticut, United States, 06360-2875
- Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
-
-
Delaware
-
Wilmington, Delaware, United States, 19803
- Alfred I. DuPont Hospital for Children
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010-2970
- Children's National Medical Center
-
Washington, District of Columbia, United States, 20007
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus
-
Augusta, Georgia, United States, 30912-3730
- MBCCOP - Medical College of Georgia Cancer Center
-
Savannah, Georgia, United States, 31403-3089
- Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
-
-
Illinois
-
Chicago, Illinois, United States, 60637-1470
- University of Chicago Cancer Research Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202-5289
- Indiana University Melvin and Bren Simon Cancer Center
-
-
Iowa
-
Iowa City, Iowa, United States, 52242-1002
- Holden Comprehensive Cancer Center at University of Iowa
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536-0093
- Lucille P. Markey Cancer Center at University of Kentucky
-
Louisville, Kentucky, United States, 40232
- Kosair Children's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-0286
- C.S. Mott Children's Hospital at University of Michigan Medical Center
-
Grand Rapids, Michigan, United States, 49503-2560
- Butterworth Hospital at Spectrum Health
-
Kalamazoo, Michigan, United States, 49007-5381
- CCOP - Kalamazoo
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis, Minnesota, United States, 55455
- Masonic Cancer Center at University of Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Cancer Center
-
St. Paul, Minnesota, United States, 55102-2392
- Children's Hospitals and Clinics of Minnesota - St. Paul
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Children's Mercy Hospital
-
-
Nevada
-
Las Vegas, Nevada, United States, 89109-2306
- CCOP - Nevada Cancer Research Foundation
-
-
New Jersey
-
Morristown, New Jersey, United States, 07962
- Overlook Hospital
-
Morristown, New Jersey, United States, 07962
- Carol G. Simon Cancer Center at Morristown Memorial Hospital
-
Paterson, New Jersey, United States, 07503
- St. Joseph's Hospital and Medical Center
-
-
New York
-
Bronx, New York, United States, 10461
- Albert Einstein Cancer Center at Albert Einstein College of Medicine
-
Mineola, New York, United States, 11501
- Winthrop University Hospital
-
New York, New York, United States, 10065
- Memorial Sloan-Kettering Cancer Center
-
New York, New York, United States, 10016
- NYU Cancer Institute at New York University Medical Center
-
New York, New York, United States, 10032
- Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
-
New York, New York, United States, 10003-3803
- Beth Israel Medical Center - Petrie Division
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599-7295
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
-
-
North Dakota
-
Fargo, North Dakota, United States, 58122
- CCOP - MeritCare Hospital
-
-
Ohio
-
Akron, Ohio, United States, 44308-1062
- Akron Children's Hospital
-
Cincinnati, Ohio, United States, 45229-3039
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Taussig Cancer Center
-
Cleveland, Ohio, United States, 44106-5000
- Rainbow Babies and Children's Hospital
-
Columbus, Ohio, United States, 43205-2696
- Nationwide Children's Hospital
-
Dayton, Ohio, United States, 45404-1815
- Dayton Children's - Dayton
-
Toledo, Ohio, United States, 43614
- Medical University of Ohio Cancer Center
-
-
Oregon
-
Portland, Oregon, United States, 97239-3098
- Knight Cancer Institute At Oregon Health and Science University
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033-0850
- Penn State Children's Hospital
-
Philadelphia, Pennsylvania, United States, 19104-9786
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, United States, 15213
- Children's Hospital of Pittsburgh of UPMC
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, United States, 57117-5039
- Sanford Cancer Center at Sanford USD Medical Center
-
-
Texas
-
Amarillo, Texas, United States, 79106
- Texas Tech University Health Sciences Center School of Medicine - Amarillo
-
Fort Worth, Texas, United States, 76104
- Cook Children's Medical Center - Fort Worth
-
Lubbock, Texas, United States, 79410
- Covenant Children's Hospital
-
San Antonio, Texas, United States, 78229-3993
- Methodist Children's Hospital of South Texas
-
-
Utah
-
Salt Lake City, Utah, United States, 84113-1100
- Primary Children's Medical Center
-
-
Virginia
-
Norfolk, Virginia, United States, 23507-1971
- Children's Hospital of The King's Daughters
-
-
Washington
-
Seattle, Washington, United States, 98105
- Children's Hospital and Regional Medical Center - Seattle
-
Seattle, Washington, United States, 98112
- Group Health Central Hospital
-
Spokane, Washington, United States, 99210-0248
- Deaconess Medical Center
-
Tacoma, Washington, United States, 98405
- Mary Bridge Children's Hospital and Health Center - Tacoma
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically proven malignant brain or spinal cord tumor, including the following:
- Primitive neuroectodermal tumor
- Ganglioneuroblastoma
- Medulloblastoma neuroblastoma
- Desmoplastic medulloblastoma
- Medulloepithelioma
- Ependymoma neuroepithelioma
- Anaplastic ependymoma germ cell tumor
- Astrocytoma germinoma
- Anaplastic astrocytoma
- Embryonal carcinoma
- Glioblastoma endodermal sinus tumor
- Gliosarcoma malignant teratoma
- Choroid plexus carcinoma
- Mixed germ cell tumor
- Cerebellar sarcoma
- Pineoblastoma
- Atypical teratoid/rhabdoid tumor
- Choriocarcinoma
- Teratoma (malignant or with malignant transformations)
- Diffusely involved brain stem tumors allowed if there is evidence of brain stem glioma by CT scan or MRI
PATIENT CHARACTERISTICS:
Age:
- 6 months to less than 3 years
Performance Status:
- Not specified
Life Expectancy:
- More than 8 weeks
Hematopoietic:
- Absolute neutrophil count greater than 1,000/mm^3
- Platelet count greater than 100,000/mm^3
Hepatic:
- Bilirubin less than 2.0 mg/dL
Renal:
- Glomerular filtration rate or creatinine clearance greater than 70 mL/min
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No prior biologic therapy
Chemotherapy:
- No prior chemotherapy
Endocrine therapy:
- Prior corticosteroids allowed
Radiotherapy:
- No prior radiotherapy
Surgery:
- No more than 6 weeks since prior surgery
- Recovered from prior surgery (stable)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (combination chemotherapy, PBSC transplant)
Pts undergo conventional surgery for diagnosis & max tumor resection.
In 6 wks of surgery or when stable pts begin induction chemotherapy(cisplatin IV over 6 hrs on day 0; vincristine sulfate IV on days 0,7,14; cyclophosphamide IV over 1 hr on days 1-2; and etoposide IV over 1 hr on days 0-2.
24 hrs after the last cyclophosphamide dose, pts receive filgrastim (G-CSF) & undergo peripheral blood stem cell harvest 2 days later.
Treatment repeats every 21 days for up to 3 crs.
Within 6 wks after induction, pts receive consolidation (carboplatin IV over 2 hrs on days 0-1 next esc.
doses of thiotepa IV over 2 hrs.
Pts undergo peripheral blood stem cell transplantation 48 hrs after last thiotepa dose.
Pts receive G-CSF SC daily on days 3-21.
Treatment repeats every 21 days for up to 3 crs.
Pts with dose-limiting toxicity due to thiotepa are removed from study.
Pts are followed at 4 wks, 3 mths for 1 yr, 6 mths for 3 yrs, annually for 3 yrs or until relapse.
|
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility
Time Frame: Up to 4 weeks after completion of study treatment
|
Demonstrate the feasibility of administering this regimen, to select an acceptable Thiotepa dose for Consolidation therapy, and to document significant toxicities and estimate their overall rates
|
Up to 4 weeks after completion of study treatment
|
Maximal tolerated dose of thiotepa for consolidation therapy
Time Frame: 9 weeks
|
The dose level will be assigned within 3 working days prior to beginning Consolidation.
|
9 weeks
|
Overall rates of significant toxicities including grade IV ototoxicity, electrolytic wasting (grade IV), and hemorrhagic cystitis (grade IV)
Time Frame: Up to 6 years
|
Estimates will be obtained using life-table methods with an event defined as the first occurrence of toxicity.
Graded using the CCG Toxicity and Complications Criteria.
|
Up to 6 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Event Free Survival
Time Frame: From the time of study entry to the first occurrence of death by any cause, progression or recurrence of disease or occurrence of a second malignant neoplasm, assessed up
|
From the time of study entry to the first occurrence of death by any cause, progression or recurrence of disease or occurrence of a second malignant neoplasm, assessed up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Bruce H. Cohen, MD, The Cleveland Clinic
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- untreated childhood brain stem glioma
- childhood high-grade cerebral astrocytoma
- disseminated neuroblastoma
- localized unresectable neuroblastoma
- stage 4S neuroblastoma
- regional neuroblastoma
- untreated childhood medulloblastoma
- untreated childhood cerebellar astrocytoma
- childhood infratentorial ependymoma
- newly diagnosed childhood ependymoma
- childhood atypical teratoid/rhabdoid tumor
- childhood supratentorial ependymoma
- childhood choroid plexus tumor
- embryonal childhood rhabdomyosarcoma
- previously untreated childhood rhabdomyosarcoma
- localized resectable neuroblastoma
- childhood low-grade cerebral astrocytoma
- untreated childhood supratentorial primitive neuroectodermal tumor
- childhood central nervous system choriocarcinoma
- childhood central nervous system embryonal tumor
- childhood central nervous system germinoma
- childhood central nervous system mixed germ cell tumor
- childhood central nervous system teratoma
- childhood central nervous system yolk sac tumor
- childhood spinal cord neoplasm
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroectodermal Tumors, Primitive
- Neuroectodermal Tumors, Primitive, Peripheral
- Neoplasms
- Brain Neoplasms
- Nervous System Neoplasms
- Central Nervous System Neoplasms
- Neuroblastoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Adjuvants, Immunologic
- Cyclophosphamide
- Carboplatin
- Etoposide
- Cisplatin
- Lenograstim
- Vincristine
- Thiotepa
Other Study ID Numbers
- 99703
- COG-99703 (Other Identifier: Children's Oncology Group)
- CCG-99703 (Other Identifier: Children's Cancer Group)
- CDR0000065924 (Other Identifier: Clinical Trials.gov)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoma
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedUterine Corpus Leiomyosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma | Stage IC Uterine SarcomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedBone Sarcoma | Retroperitoneal Sarcoma | Adult Soft Tissue SarcomaUnited States
-
Mohammed M MilhemGenentech, Inc.CompletedSarcoma | Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma | MPNST | High-risk SarcomaUnited States
-
Epizyme, Inc.RecruitingAdvanced Soft-tissue Sarcoma | Advanced Epithelioid SarcomaUnited States, Taiwan, Canada, United Kingdom
-
Brown UniversityActuate Therapeutics Inc.WithdrawnSoft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma of Bone | Leiomyosarcoma | High Grade Sarcoma | Liposarcoma | Rhabdomyosarcoma | Angiosarcoma | Bone Sarcoma | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma | Spindle Cell SarcomaUnited States
-
David DickensWithdrawnSoft Tissue Sarcoma | Bone Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft-tissue Sarcoma | Metastatic Bone Sarcoma | Unresectable Bone SarcomaUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma
Clinical Trials on cyclophosphamide
-
Children's Hospital Los AngelesLucile Packard Children's HospitalTerminatedMetabolic Diseases | Stem Cell Transplantation | Chronic Granulomatous Disease | Bone Marrow Transplantation | Thalassemia | Wiskott-Aldrich Syndrome | Genetic Diseases | Peripheral Blood Stem Cell Transplantation | Pediatrics | Diamond-Blackfan Anemia | Allogeneic Transplantation | Combined Immune Deficiency | X-linked Lymphoproliferative Disease
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedAnemia, AplasticUnited States
-
Columbia UniversityUnknownSevere Combined Immunodeficiency | Fanconi Anemia | Bone Marrow Failure | OsteopetrosisUnited States
-
National Cancer Institute, NaplesImmatics Biotechnologies GmbH; CureVac; European Commission -FP7-Health-2013-Innovation-1CompletedHepatocellular CarcinomaBelgium, Germany, Italy, Spain, United Kingdom
-
Mahidol UniversityTerminatedRenal Insufficiency | InfectionThailand
-
Centre Oscar LambretCompleted
-
Eisai Inc.CompletedBreast Cancer | Ovarian Cancer | Prostate Cancer | Colon Cancer | Renal CancerUnited States
-
Baylor Research InstituteCompletedMalignant Melanoma Stage IVUnited States
-
University of Turin, ItalyUnknown
-
Merck KGaA, Darmstadt, GermanyCompleted